VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma

International Journal of Biochemistry and Cell Biology

Volumn 41, Issue 4, 2009, Pages 753-756

  Linehan, W Marston ^a   Rubin, Jeffrey S ^a   Bottaro, Donald P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Catenin; HGF; HIF; Oncogenesis; Renal cell carcinoma; VHL

Indexed keywords

BETA CATENIN; GENE PRODUCT; HYPOXIA INDUCIBLE FACTOR; PROTEASOME; SCATTER FACTOR; UBIQUITIN PROTEIN LIGASE; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; CANCER INVASION; CARCINOGENESIS; CELL PROLIFERATION; CLEAR CELL CARCINOMA; ENZYME DEGRADATION; GENE EXPRESSION; GENE FUNCTION; GENE LOSS; HOMEOSTASIS; HUMAN; KIDNEY CARCINOMA; KIDNEY DEVELOPMENT; METABOLISM; METASTASIS; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UBIQUITINATION;

ANIMALS; BETA CATENIN; CARCINOMA, RENAL CELL; GENE EXPRESSION; HUMANS; KIDNEY NEOPLASMS; SIGNAL TRANSDUCTION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 59649129136     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.09.024     Document Type: Short Survey

References (22)

1. Bernhardt W.M., Schmitt R., Rosenberger C., Munchenhagen P.M., Grone H.J., Frei U., et al. Expression of hypoxia-inducible transcription factors in developing human and rat kidneys. Kidney Int 69 (2006) 114-122
2. Birchmeier C., Birchmeier W., Gherardi E., and Vande Woude G.F. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4 (2003) 915-925
3. Brembeck F.H., Schwarz-Romond T., Bakkers J., Wilhelm S., Hammerschmidt M., and Birchmeier W. Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions. Genes Dev 18 (2004) 2225-2230
4. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 127 (2006) 469-480
5. Dahl E., Wiesmann F., Woenckhaus M., Stoehr R., Wild P.J., Veeck J., et al. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene 26 (2007) 5680-5691
6. Dressler G.R. The cellular basis of kidney development. Annu Rev Cell Dev Biol 22 (2006) 509-529
7. Guillen-Ahlers H. Wnt signaling in renal cancer. Curr Drug Targets 9 (2008) 591-600
8. Gumz M.L., Zou H., Kreinest P.A., Childs A.C., Belmonte L.S., LeGrand S.N., et al. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 13 (2007) 4740-4749
9. Huber S.M., Braun G.S., Segerer S., Veh R.W., and Horster M.F. Metanephrogenic mesenchyme-to-epithelium transition induces profound expression changes of ion channels. Am J Physiol Renal Physiol 279 (2000) F65-F76
10. Kaelin Jr. W.G. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2 (2002) 673-682
11. Kaidi A., Williams A.C., and Paraskeva C. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 9 (2007) 210-217
12. Kurose K., Sakaguchi M., Nasu Y., Ebara S., Kaku H., Kariyama R., et al. Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma. J Urol 171 (2004) 1314-1318
13. Linehan W.M., Pinto P.A., Srinivasan R., Merino M., Choyke P., Choyke L., et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 13 (2007) 671s-679s
14. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 69 (2006) 213-217
15. Matsumoto K., and Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases 64. Kidney Int 59 (2001) 2023-2038
16. Perantoni A.O. Renal development: perspectives on a Wnt-dependent process. Semin Cell Dev Biol 14 (2003) 201-208
17. Peruzzi B., Athauda G., and Bottaro D.P. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci U S A 103 (2006) 14531-14536
18. Richards F.M., Schofield P.N., Fleming S., and Maher E.R. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 5 (1996) 639-644
19. Rubin J.S., Barshishat-Kupper M., Feroze-Merzoug F., and Xi Z.F. Secreted WNT antagonists as tumor suppressors: pro and con. Front Biosci 11 (2006) 2093-2105
20. Russell R.C., and Ohh M. The role of VHL in the regulation of E-cadherin: a new connection in an old pathway. Cell Cycle 6 (2007) 56-59
21. Urakami S., Shiina H., Enokida H., Hirata H., Kawamoto K., Kawakami T., et al. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 12 (2006) 6989-6997
22. van Adelsberg J., Sehgal S., Kukes A., Brady C., Barasch J., Yang J., et al. Activation of hepatocyte growth factor (HGF) by endogenous HGF activator is required for metanephric kidney morphogenesis in vitro. J Biol Chem 276 (2001) 15099-15106